PCI Biotech: Independent Data Monitoring Committee recommends continuation of two treatments in the RELEASE trial
Oslo (Norway), 13 December 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the Independent Data Monitoring Committee (IDMC) has reviewed the safety data collected thus far in the RELEASE trial and recommends that the trial continues with up to two fimaChem treatments as stated in the protocol.
The ongoing pivotal RELEASE trial with registration intent was initiated with a planned safety review for the first eight patients receiving two fimaChem treatments. In the previously completed Phase I study a total of five patients received two treatments and now with additional eight patients reviewed for safety after two treatments, the RELEASE trial seamlessly continues to enrol patients for up to two fimaChem treatments.
Per Walday, CEO of PCI Biotech, said: “With this positive initial safety clearance for repeated treatments, PCI Biotech continue to focus on execution of the pivotal trial and we are eager to see the benefits fimaChem hopefully can provide to the patients in need of better local treatment options.So far, a clear majority of patients eligible to receive two treatments in RELEASE opted for thesecond treatment, which is an early encouraging sign on the acceptability of the treatment modality, both from a patient- and clinician perspective."
The IDMC consists of international experts in bile duct cancer and medical statistics and is chartered to monitor the safety of participants in the RELEASE trial. The primary purpose of the IDMC is the protection of participants in the trial and the maintenance of trial integrity. The IDMC recommendation is based on a review of the available trial safety data, including data from eight patients that had undergone two fimaChem treatments.
About PCI Biotech
PCI Biotech is a biopharmaceutical late-stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in perihilar and distal bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
Per Walday, CEO
Mobile: +47 917 93 429
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
BIGBEN: Report of the Combined General Meeting of 28 January 202228.1.2022 17:45:00 CET | Press release
Report of the Combined General Meeting of 28 January 2022 The combined shareholders’ meeting (ordinary and extraordinary) of the BIGBEN INTERACTIVE company taking place at Lesquin headquarters on Friday 28 January 2022 at 11:00 hours, adopted all the proposed resolutions after the presentation of legal documents. 540 shareholders attending or represented owned 12 585 016 shares out of 19 303 597 shares with voting rights, i.e. 65.19 % and as such over one fourth of the share capital with voting rights. These shares represented 15 121 184 votes i.e. 68.40 % of net voting rights. Number of shares outstanding as of 28 January 202219 380 484Number of shares with voting rigths19 303 597Number of voting rights (net)22 104 126 Adoption ofresolutions N°Description of resolutionsFor%Against%1Amendment of the Articles of Association (distribution of profits)Extraord.15 115 52799.983 6050.022Exceptional distribution in kind of Nacon sharesOrdinary15 117 07099.983 1070.023Powers to fulfill legal f
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS28.1.2022 16:20:00 CET | Press release
Bid procedure, 2022-02-03BondsSWEDBANK HYPOTEK AB: 193. SE0011089622. 2023-12-20 STADSHYPOTEK AB: 1587, SE0010441303, 2023-06-01 SWEDISH COVERED BOND: 151, SE0013486156, 2030-06-12 SKANDINAVISKA ENSKILDA: 581, SE0013102043, 2026-12-16 LANSFORSAKRINGAR HYPOTEK: 521, SE0015503446, 2028-09-20 DANSKE HYPOTEK AB: 2612, SE0015987540, 2026-12-16 NORDEA HYPOTEK AB: 5536, SE0013358439, 2026-09-16 Bid date2022-02-03Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)193: 200 mln SEK +/-100 mln SEK 1587: 900 mln SEK +/-450 mln SEK 151: 200 mln SEK +/-100 mln SEK 581: 200 mln SEK +/-100 mln SEK 521: 300 mln SEK +/-150 mln SEK 2612: 100 mln SEK +/-50 mln SEK 5536: 600 mln SEK +/-300 mln SEK Highest permitted bid volume (corresponding nominal amount)193: 200 mln SEK per bid 1587: 900 mln SEK per bid 151: 200 mln SEK per bid 581: 200 mln SEK per bid 521: 300 mln SEK per bid 2612: 100 mln SEK per bid 5536: 600 mln SEK per bid Lowest permitted bid volume (corre
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS28.1.2022 16:20:00 CET | Press release
Anbudsförfarande kommuner och regioner, 2022-02-01BondsFixed rate notes issued in SEK by Municipalities or Regions with maturity in: 2025 The following issuers are accepted for delivery: BORÅS KOMMUN GÖTEBORGS KOMMUN HELSINGBORGS KOMMUN HUDDINGE KOMMUN JÖNKÖPINGS KOMMUN MALMÖ KOMMUN NACKA KOMMUN SKÅNE LÄNS LANDSTING STOCKHOLMS KOMMUN STOCKHOLMS LÄNS LANDSTING VELLINGE KOMMUN VÄSTERÅS KOMMUN Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after: 2022-01-21BidsBids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se Bid date2022-02-01Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 750 +/- 750 millionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not e
CONDITIONS FOR PURCHASES OF CORPORATE BONDS28.1.2022 16:20:00 CET | Press release
Bid procedure, 2022-02-02BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: STOCKHOLM EXERGI HOLD: SE0012193829, 2026-09-11 FORTUM VARME HOLDING SAM: SE0010599019, 2025-02-24 SPECIALFASTIGHETER SVERI: SE0010600270, 2024-11-28 SPECIALFASTIGHETER SVERI: SE0011869916, 2025-05-12 HOLMEN AB: SE0013359437, 2024-10-29 HOLMEN AB: SE0012676708, 2025-02-12 ELECTROLUX AB: XS2152294679, 2023-04-06 ELECTROLUX AB: XS2081016920, 2024-11-19 INVESTMENT AB LATOUR: SE0012676518, 2024-09-25 INVESTMENT AB LATOUR: SE0013101730, 2025-09-16 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2022-01-02Bid date2022-02-02Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SE0012193829: 30 mln SEK +/-30 mln SEK SE0010599019: 30 mln SEK
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS28.1.2022 16:20:00 CET | Press release
Bid procedure, 2022-02-04BondsSWEDISH GOVERNMENT: 1056. SE0004517290. 2032-06-01 SWEDISH GOVERNMENT: 1063, SE0015193313, 2045-11-24 Bid date2022-02-04Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1056: 1000 mln SEK +/-500 mln SEK 1063: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)1056: 1000 mln SEK per bid 1063: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2022-02-08Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2022-01-28 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions
JLT Mobile Computers AB ger i enlighet med tidigare lämnad information ut aktier till säljaren av ID Work28.1.2022 15:48:27 CET | Pressemelding
JLT Mobile Computers AB ger i enlighet med tidigare lämnad information ut aktier till säljaren av ID Work Växjö, Sverige, 28:e januari2022 * * * JLT Mobile Computers, ledande leverantör av stryktåliga datorer för krävande miljöer, meddelar idag att de i enlighet med pressmeddelande från den 11:e januari, 2022 ger ut aktier till säljaren av det förvärvade bolaget ID Work. Det annonserades då att JLT Mobile Computers har förvärvat samtliga aktier i den franska säljpartnern ID Work, varvid del av köpeskillingen skulle erläggas med nya aktier i JLT Mobile Computers. Mot bakgrund av ovan har styrelsen för JLT Mobile Computers idag, med stöd av bolagstämmans bemyndigande, beslutat att ge ut 160 000 nya aktier. Aktierna ges ut till säljarna av ID Work och betalas genom kvittning av fordran om sammanlagt 100 000 EUR på JLT Mobile Computers, motsvarande en teckningskurs om 6,50 kronor per aktie. Kursen är satt efter vad som gällde vid tidpunkten för anbudet att förvärva bolaget. Skälet till avv